 |
|
|
| |
CLINICAL OUTCOMES DURING CUSTOMIZE: A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY FOCUSED ON IMPLEMENTATION OF CABOTEGRAVIR PLUS RILPIVIRINE (CAB + RPV) LA IN US HEALTHCARE SETTINGS
|
| |
| |
IAS 2021 July 18-22
Gary Sinclair,1 Paul Benson,2 Leandro Mena,3 Maggie Czarnogorski,4 Cindy Garris,4 Marybeth Dalessandro,5 Sterling Wu,6 Deanna Merrill,4 Toyin Nwafor,4 Ronald D’Amico4
1AIDS Arms, Inc, Dallas, TX, USA; 2Be Well Medical Center, Berkley, MI, USA; 3University of Mississippi Medical Center, Jackson, MS, USA; 4ViiV Healthcare, Research Triangle Park, NC, USA;
5ViiV Healthcare, Collegeville, PA, USA; 6GlaxoSmithKline, Collegeville, PA, USA
|
| |
|
|
|
|
|
